Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Reid JH, Marini BL, Nachar VR, et al. Contemporary treatment options for a classical disease: advanced Hodgkin lymphoma. Crit Rev Oncol Hematol. 2020;148:102897.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sattarzadeh A, Diepstra A, et al. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Semin Cancer Biol. 2014;24:15–22.
   PubMed Web of Science ®Google Scholar
• Pedoeem A, Azoulay-Alfaguter I, Strazza M, et al. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol. 2014;153(1):145–152.
   PubMed Web of Science ®Google Scholar
• Hollander P, Kamper P, Smedby KE, et al. High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome. Blood Adv. 2017;1(18):1427–1439.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Corrales L, Williams J, et al. Cancer immunotherapy targets based on understanding the t cell-inflamed versus Non-T cell-inflamed tumor microenvironment. Adv Exp Med Biol. 2017;1036:19–31.
   PubMed Web of Science ®Google Scholar
• Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185(9):4977–4982.
   PubMed Web of Science ®Google Scholar
• Tudor CS, Distel LV, Eckhardt J, et al. B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. Hum Pathol. 2013;44(11):2475–2486.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Greaves P, Clear A, Owen A, et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood. 2013;122(16):2856–2863.
   PubMed Web of Science ®Google Scholar
• Cader FZ, Schackmann RCJ, Hu X, et al. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood. 2018;132(8):825–836.
   PubMed Web of Science ®Google Scholar
• Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. J Clin Oncol. 2007;25(21):3101–3108.
   PubMed Web of Science ®Google Scholar
• Vari F, Arpon D, Keane C, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131(16):1809–1819.
   PubMed Web of Science ®Google Scholar
• Alka M, Chatterjeeb S, Parchure A, et al. Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children—A preliminary observation. Immunobiol. 2020;225:151907.
   PubMed Web of Science ®Google Scholar
• Ghadially H, Brown L, Lloyd C, et al. MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue. Br J Cancer. 2017;116(9):1208–1217.
   PubMed Web of Science ®Google Scholar
• Camodeca C, Nuti E, Tepshi L, et al. Discovery of a new selective inhibitor of A disintegrin and metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin’s lymphoma cell models. Eur J Med Chem. 2016;111:193–201.
   PubMed Web of Science ®Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–1636.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Perales MA, Kewalramani T, et al. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol. 2009;146(2):158–163.
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Kreher S, Anagnostopoulos I, et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood. 2008;112(8):3339–3347.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–5391.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, et al. Prognostic implication of absolute lymphocyte to absolute monocyte count ratio in patients with classical Hodgkin lymphoma treated with Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or equivalent regimens. Oncologist. 2016;21(3):343–353.
   PubMed Web of Science ®Google Scholar
• Jachimowicz RD, Pieper J, Reinke S, et al. Analysis of the tumor microenvironment by whole-slide image analysis identifies low B cell content as a predictor of adverse outcome in advanced-stage classical Hodgkin lymphoma treated with BEACOPP. Haematologica. 2019;2019:243287.
   Google Scholar
• Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020;26(9):1468–1479.
   PubMed Web of Science ®Google Scholar
• Scott DW, Steidl C. The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling. Hematol Am Soc Hematol Educ Program. 2014;2014(1):144–150.
   PubMedGoogle Scholar
• Gattringer G, Greil R, Radaszkiewicz T, et al. In situ quantification of T-cell subsets, NK-like cells and macrophages in Hodgkin’s disease: quantity and quality of infiltration density depends on histopathological subtypes. Blut. 1986;53(1):49–58.
   PubMedGoogle Scholar
• Diepstra A, Poppema S, Boot M, et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma. Tissue Antigens. 2008;71(3):219–226.
   PubMedGoogle Scholar
• Ayoub JP, Palmer JL, Huh Y, et al. Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin’s disease. Leuk Lymphoma. 1999;34(5–6):519–527.
   PubMed Web of Science ®Google Scholar
• Chiu J, Ernst DM, Keating A. Acquired natural killer cell dysfunction in the tumor microenvironment of classic Hodgkin lymphoma. Front Immunol. 2018;9:267.
   PubMed Web of Science ®Google Scholar
• Fais F, Morabito F, Stelitano C, et al. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer. 2004;109(3):402–411.
   PubMed Web of Science ®Google Scholar
• Dhodapkar M, Geller M, Chang D, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant Multiple myeloma. J Exp Med. 2003;197(12):1667–1676.
   PubMed Web of Science ®Google Scholar
• Xu C, Vries R, Visser L, et al. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. Am J Hematol. 2010;85(7):539–541.
   PubMed Web of Science ®Google Scholar
• Ma Y, Visser L, Blokzijl T, et al. The CD4 + CD26-T-cell population in classical Hodgkin’s lymphoma displays a distinctive regulatory T-cell profile. Lab Invest. 2008;88(5):482–490.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Niu C, Cui J. Gamma-delta (γδ) T cells: friend or foe in cancer development? J Transl Med. 2018;16(1):3.
   PubMedGoogle Scholar
• Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389–1396.
   PubMed Web of Science ®Google Scholar
• Street SE, Hayakawa Y, Zhan Y, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med. 2004;199(6):879–884.
   PubMed Web of Science ®Google Scholar
• Gaafar A, Aljurf MD, Al-Sulaiman A, et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol. 2009;37(7):838–848.
   PubMed Web of Science ®Google Scholar
• Zocchi MP, Catellani S, Canevali P, et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood. 2012;119(6):1479–1489.
   PubMed Web of Science ®Google Scholar
• Fernandez-Messina L, Ashiiru O, Boutet P, et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem. 2010;285(12):8543–8551.
   PubMed Web of Science ®Google Scholar
• Reiners KS, Kessler J, Sauer M, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21(4):895–903.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36(10):942–950.
   PubMed Web of Science ®Google Scholar